FLT1 and renal cell adenocarcinoma: VEGF has been shown to promote the expansion of “MDSCs” (31) and decreased numbers of CD11b+ VEGFR1 + MDSCs in the peripheral blood were observed in the peripheral blood of renal cell cancer (RCC) patients treated with the anti-VEGF antibody bevacizumab.